Published in J Hepatol on February 16, 2010
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One (2014) 1.43
A new role for an old marker, HBsAg. J Hepatol (2010) 1.12
Management of hepatitis B in developing countries. World J Hepatol (2011) 1.08
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol (2013) 1.03
High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One (2012) 1.01
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol (2012) 0.99
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int (2012) 0.98
Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol (2013) 0.96
A mouse model for HBV immunotolerance and immunotherapy. Cell Mol Immunol (2013) 0.93
Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol (2012) 0.91
Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol (2014) 0.90
The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol (2014) 0.88
Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med (2014) 0.88
Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) (2014) 0.87
Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact. PLoS One (2012) 0.86
Hepatitis B virus large surface protein: function and fame. Hepatobiliary Surg Nutr (2015) 0.86
Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China. Hepat Mon (2015) 0.84
Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol (2014) 0.83
Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol (2015) 0.82
IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One (2013) 0.81
Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS One (2012) 0.81
Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study. World J Gastroenterol (2014) 0.80
Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One (2013) 0.80
Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur J Microbiol (2015) 0.80
Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med (2016) 0.79
Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B. BMC Infect Dis (2015) 0.79
Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients. Ann Lab Med (2012) 0.79
Evaluation of changes of serum hepatitis B surface antigen from a different perspective. World J Gastroenterol (2015) 0.78
Potential mechanisms of hepatitis B virus induced liver injury. World J Gastroenterol (2014) 0.78
Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol (2011) 0.78
Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol (2011) 0.78
A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore) (2016) 0.78
Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Hepatol Int (2012) 0.78
Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment. Hepat Mon (2012) 0.77
Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load. Am J Cancer Res (2015) 0.77
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol (2014) 0.77
Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. World J Gastroenterol (2014) 0.77
Diagnosis of hepatitis B. Ann Transl Med (2016) 0.77
Community-based prevention of hepatitis-B-related liver cancer: Australian insights. Bull World Health Organ (2014) 0.76
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus. Clin Vaccine Immunol (2011) 0.76
Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol (2014) 0.76
Serum hepatitis B surface antigen titer and transient elastography in screening for insignificant fibrosis in HBeAg-positive chronic hepatitis B patients. Ther Clin Risk Manag (2015) 0.76
Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients. PLoS One (2014) 0.76
Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis (2016) 0.75
Correlation between HBsAg quantitation and HBV DNA in HBeAg-negative HBV/D patients. Saudi J Gastroenterol (2013) 0.75
Dose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women. Int J Cancer (2016) 0.75
Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV DNA Levels in the Natural History of Hepatitis B Virus Infection. J Clin Exp Hepatol (2016) 0.75
HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J (2016) 0.75
On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol (2016) 0.75
Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection. Prz Gastroenterol (2014) 0.75
A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine. Hepat Mon (2016) 0.75
HBsAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. J Clin Exp Hepatol (2015) 0.75
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis (2016) 0.75
Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. Gut Liver (2015) 0.75
Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. Chin Med J (Engl) (2017) 0.75
HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions. World J Gastroenterol (2014) 0.75
HBsAg level and hepatitis B viral load correlation with focus on pregnancy. Ann Gastroenterol (2015) 0.75
Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection. Virol J (2015) 0.75
HBsAg Quantification in Clinical Practice. J Clin Exp Hepatol (2012) 0.75
Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS One (2015) 0.75
Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase. World J Gastroenterol (2016) 0.75
Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol (2013) 0.75
Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection. Clin Vaccine Immunol (2014) 0.75
Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis. Eur J Clin Microbiol Infect Dis (2015) 0.75
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver (2017) 0.75
Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology (2013) 3.55
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust (2009) 2.42
The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol (2013) 2.41
Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol (2007) 2.24
Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int (2010) 2.12
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis (2014) 2.02
SINGLE-01: a randomized, controlled trial comparing the efficacy and depth of insertion of single- and double-balloon enteroscopy by using a novel method to determine insertion depth. Gastrointest Endosc (2012) 1.91
Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res (2003) 1.88
Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol (2009) 1.67
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol (2007) 1.54
Initial experience with capsule endoscopy at a major referral hospital. Med J Aust (2003) 1.54
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Prospective study of the clinical impact of EUS. Gastrointest Endosc (2005) 1.49
Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol (2002) 1.45
BK virus-associated progressive multifocal leukoencephalopathy. Med J Aust (2013) 1.41
Noninvasive imaging of the small bowel in Crohn's disease: the final frontier. Inflamm Bowel Dis (2011) 1.40
Resistance to anti-HCV protease inhibitors. Curr Opin Virol (2011) 1.30
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2007) 1.28
Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology (2002) 1.28
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis (2006) 1.27
Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis (2011) 1.24
The effect of erythromycin on video capsule endoscopy intestinal-transit time. Gastrointest Endosc (2006) 1.22
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology (2003) 1.21
SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res (2006) 1.16
Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care (2005) 1.14
Prospective assessment of magnetic resonance cholangiopancreatography for noninvasive imaging of the biliary tree. Gastrointest Endosc (2002) 1.09
Confocal endomicroscopy for in vivo detection of microvascular architecture in normal and malignant lesions of upper gastrointestinal tract. J Gastroenterol Hepatol (2007) 1.08
UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos (2002) 1.08
Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther (2007) 1.08
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One (2012) 1.07
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology (2009) 1.03
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology (2011) 1.03
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology (2007) 1.00
Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. J Gastroenterol Hepatol (2012) 0.99
Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol (2006) 0.97
Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol (2010) 0.97
Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther (2010) 0.97
Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroenterol Hepatol (2015) 0.96
Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.96
Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience. J Gastroenterol Hepatol (2012) 0.95
Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome. J Gastroenterol (2006) 0.95
Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol (2007) 0.95
Plasma and gastric mucosal 5-hydroxytryptamine concentrations following cold water intake in patients with diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol (2007) 0.93
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis (2013) 0.93
Molecular epidemiology of hepatitis B in the Indigenous people of northern Australia. J Gastroenterol Hepatol (2013) 0.93
High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis (2010) 0.93
Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol (2011) 0.92
Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J Gastroenterol Hepatol (2009) 0.92
Structural and functional analysis of Aplysia attractins, a family of water-borne protein pheromones with interspecific attractiveness. Proc Natl Acad Sci U S A (2004) 0.90
Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology (2012) 0.89
Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs (2002) 0.89
Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS (2007) 0.88
Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS (2011) 0.88
Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol (2004) 0.88
Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood (2005) 0.86
Indications of immune protection from hepatitis C infection. J Urban Health (2004) 0.86
Change in hepatitis C virus genotype in injecting drug users. J Med Virol (2004) 0.86
Altered immune system glycosylation causes colitis in alpha1,2-fucosyltransferase transgenic mice. Inflamm Bowel Dis (2004) 0.84
Drug resistance in antiviral therapy. Clin Liver Dis (2010) 0.84
High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One (2013) 0.83
Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol (2004) 0.83
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther (2010) 0.83
Human 5-HT(4) and 5-HT(7) receptor splice variants: are they important? Curr Neuropharmacol (2007) 0.83
Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver. Liver Int (2010) 0.83
Dysplastic lesions in ulcerative colitis: changing paradigms. Inflamm Bowel Dis (2010) 0.83
Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol (2003) 0.83
Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol (2015) 0.83
Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at -20°C and -70°C. J Clin Microbiol (2011) 0.82
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology (2009) 0.82
Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol (2013) 0.82
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol (2013) 0.82
Decreased viral load and symptoms of polyomavirus-associated chronic interstitial cystitis after intravesical cidofovir treatment. Clin Infect Dis (2009) 0.81
Hepatitis C--an update. Aust Fam Physician (2013) 0.81
Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection. Clin Liver Dis (2011) 0.81
Advances in the molecular diagnosis of hepatitis B infection: providing insight into the next generation of disease. Semin Liver Dis (2013) 0.81
In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection. J Med Virol (2012) 0.81
Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology (2011) 0.81